Status:

COMPLETED

Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Institut National de la Santé Et de la Recherche Médicale, France

Commissariat A L'energie Atomique

Conditions:

COVID-19 Infection

Eligibility:

All Genders

7+ years

Phase:

NA

Brief Summary

The purpose of this study is to provide data on the proportion of seroconverted children and their immune status. It will also provide insight into the number of children currently infected at each ti...

Detailed Description

The fraction of undiagnosed but likely to transmit the virus is a critical epidemiological characteristic that modulates the epidemic potential of SARS-CoV2. To adapt the epidemy control, it is essent...

Eligibility Criteria

Inclusion

  • For hospitalized children or consulting at hospital
  • any child over 7 days old and under 17 years old in consultation or hospitalized for at most 4 days at AP-HP or CH Cayenne; Or any child over 7 days old and under 17 years old with a positive PCR at home, with an attending physician in a participating centre
  • Parent's agreement for blood, saliva and stool samples
  • Optional parent's agreement for nasopharynx swab
  • Optional parent's agreement for follow-up if PCR+
  • With an Health insurance
  • For children with potential COVID disease during the first wave
  • Any child over 7 days old and under 17 years, seropositive during the first wave
  • Or any child over 7 days old and under 17 years, with a previous inflammatory clinical disease potentially linked to SARS-cov2
  • With an Health insurance
  • Parent of the enrolled child
  • One parent of the enrolled child on ped-covid
  • Agreement for blood and saliva samples
  • Optional agreement for nasopharynx swab
  • Optional parent's agreement for follow-up if PCR+
  • With an Health insurance
  • For children SARS-coV2 positive
  • any child less then 18 years old
  • infected by SARS-coV2
  • Parent's agreement for blood, saliva samples
  • Optional parent's agreement for nasopharynx swab
  • With health insurance
  • For people living under the same roof of a child included in the study
  • any child or adult living under the same roof of a child SARS-coV2 positive and included in the study
  • With health insurance

Exclusion

  • For hospitalized children or consulting at hospital
  • child younger than 7 days
  • Refusal of parent
  • Refusal of child
  • No health insurance

Key Trial Info

Start Date :

July 29 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 24 2022

Estimated Enrollment :

1056 Patients enrolled

Trial Details

Trial ID

NCT04355533

Start Date

July 29 2020

End Date

May 24 2022

Last Update

January 6 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hôpital necker Enfants-Malades

Paris, France, 75015